{
    "clinical_study": {
        "@rank": "41957", 
        "acronym": "KETOPROG", 
        "arm_group": [
            {
                "arm_group_label": "Keto-diet (KD)", 
                "arm_group_type": "Experimental", 
                "description": "Patients in the intervention arm (KD group) will receive a vegetarian very low protein diet (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril\u00ae, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day."
            }, 
            {
                "arm_group_label": "Low Protein Diet group (LPD)", 
                "arm_group_type": "Active Comparator", 
                "description": "The patients in the control arm (LPD group) will continue their conventional low protein diet, with 0.6 g/kg per day (including high biological value proteins).\nThe total recommended energy intake is of 30 kcal/kg of ideal dry body weight per day in both arms."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective single center randomized controlled trial with a total duration of 18\n      months aiming to evaluate the effectiveness and the safety of a very low protein diet\n      supplemented with ketoanalogues of essential aminoacids in reducing the progression of\n      chronic kidney disease (CKD) in patients with advanced CKD."
        }, 
        "brief_title": "Supplemented Very Low Protein Diet and the Progression of Chronic Kidney Disease", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Kidney Disease", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "All eligible patients who will give informed consent will be screened. Those meeting the\n      selection criteria will be enrolled and will enter a 3-month run-in phase during which a\n      conventional LPD will be prescribed in all patients.\n\n      At the end of this phase, the subjects still fulfilling all the selection criteria will be\n      randomized in a 1:1 ratio to receive the KD or to continue the conventional LPD for a total\n      duration of 15 months.\n\n      Nineteen blood and urine samplings are scheduled for each patient, to be drawn monthly. The\n      laboratory reports include the nitrogen compounds, calcium-phosphorus metabolism parameters,\n      acid-base balance, biochemical nutritional markers, serum C-reactive protein, hemoglobin,\n      blood cell count, and biochemical safety parameters (sodium, potassium, liver enzymes, and\n      bilirubin).\n\n      The anthropometric measurements and subjective global assessment will be evaluated at\n      enrolment, at randomization, and every 3 months thereafter.\n\n      The compliance with the prescribed diet (protein and energy intake) will be assessed monthly\n      during the run-in phase, weekly for the first month after randomization, every 4 weeks\n      during the next 6 months, and every 3 months thereafter.\n\n      The blood pressure levels, drugs required for the therapy of hypertension, acidosis and\n      mineral metabolism disorders, and occurrence of adverse events will be recorded monthly."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult non-diabetic patients\n\n          -  stage 4-5 CKD not on dialysis (estimated glomerular filtration by Modification of\n             Diet in Renal Disease formula < 30 mL/min per year\n\n          -  stable renal function at least 12 weeks before enrollment\n\n          -  well-controlled arterial blood pressure\n\n          -  proteinuria less than 1 g/g urinary creatinine\n\n          -  good nutritional status\n\n          -  declared and anticipated good compliance with the prescribed diet\n\n        Exclusion Criteria:\n\n          -  poorly controlled arterial blood pressure (\u2265145/85 mm Hg)\n\n          -  relevant comorbid conditions (diabetes mellitus, heart failure, active hepatic\n             disease, digestive diseases with malabsorption, inflammation/anti-inflammatory\n             therapy)\n\n          -  uremic complications (pericarditis, polyneuropathy)\n\n          -  feeding inability (anorexia, nausea)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02031224", 
            "org_study_id": "AWG13/2007"
        }, 
        "intervention": [
            {
                "arm_group_label": "Low Protein Diet group (LPD)", 
                "intervention_name": "Conventional low protein diet", 
                "intervention_type": "Behavioral", 
                "other_name": [
                    "LPD", 
                    "Hypoproteic diet"
                ]
            }, 
            {
                "arm_group_label": "Keto-diet (KD)", 
                "intervention_name": "Very low protein diet supplemented with Ketosteril", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "SVLPD, Keto-diet"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chronic Kidney Disease", 
            "Restricted protein diets", 
            "Nutritional status"
        ], 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "contact": {
                "email": "lilianagarna@yahoo.com", 
                "last_name": "Liliana Garneata, MD, PhD", 
                "phone": "+40722619358"
            }, 
            "facility": {
                "address": {
                    "city": "Bucharest", 
                    "country": "Romania", 
                    "zip": "010731"
                }, 
                "name": "\"Dr Carol Davila\" Teaching Hospital of Nephrology"
            }, 
            "investigator": [
                {
                    "last_name": "Liliana Garneata, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Gabriel Mircescu, Professor, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Alexandra Corbu Stancu, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Diana Ramona Dragomir, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Romania"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Very Low Protein Diet Supplemented With Ketoanalogues of the Essential Amino Acids on the Progression of Chronic Kidney Disease", 
        "other_outcome": [
            {
                "description": "urinary urea nitrogen excretion to calculate the protein intake", 
                "measure": "Compliance - protein intake", 
                "safety_issue": "Yes", 
                "time_frame": "18 months after enrolment"
            }, 
            {
                "description": "3-day food diary to calculate the daily energy intake", 
                "measure": "Compliance - energy intake", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks after enrolment"
            }
        ], 
        "overall_contact": {
            "email": "lilianagarna@yahoo.com", 
            "last_name": "Liliana Garneata, MD, PhD", 
            "phone": "+40722619358"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Romania: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Need for renal replacement therapy or an at least 50% reduction in the estimated glomerular filtration rate compared to randomization", 
            "measure": "Primary composite endpoint", 
            "safety_issue": "No", 
            "time_frame": "15 months after randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02031224"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Carol Davila University of Medicine and Pharmacy", 
            "investigator_full_name": "Liliana Garneata", 
            "investigator_title": "Assistant Professor of Nephrology, MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "17462550", 
            "citation": "Mircescu G, G\u00e2rnea\u0163\u0103 L, Stancu SH, C\u0103pu\u015f\u0103 C. Effects of a supplemented hypoproteic diet in chronic kidney disease. J Ren Nutr. 2007 May;17(3):179-88."
        }, 
        "secondary_outcome": [
            {
                "description": "The rate of decline in the estimated Glomerular Filtration Rate", 
                "measure": "Secondary efficacy parameter", 
                "safety_issue": "No", 
                "time_frame": "months 3-15 after randomization"
            }, 
            {
                "description": "variations in serum urea", 
                "measure": "Secondary outcome measure - nitrogen balance", 
                "safety_issue": "No", 
                "time_frame": "15 months after randomization"
            }, 
            {
                "description": "variations in total serum calcium", 
                "measure": "Secondary efficacy parameter - mineral metabolism", 
                "safety_issue": "No", 
                "time_frame": "15 weeks after randomization"
            }, 
            {
                "description": "variations in serum phosphate level", 
                "measure": "Secondary efficacy parameter", 
                "safety_issue": "No", 
                "time_frame": "15 weeks after randomization"
            }, 
            {
                "description": "variations in serum bicarbonate", 
                "measure": "Secondary efficacy parameter", 
                "safety_issue": "No", 
                "time_frame": "15 weeks after randomization"
            }, 
            {
                "description": "Subjective Global Assessment of the nutritional status", 
                "measure": "Secondary safety parameter", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks after enrolment"
            }, 
            {
                "description": "Body Mass Index", 
                "measure": "Secondary safety parameter", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks after enrolment"
            }, 
            {
                "description": "Tricipital skinfold", 
                "measure": "Secondary outcome measure - Nutritional status", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks after enrolment"
            }, 
            {
                "description": "Mid-arm muscular circumference", 
                "measure": "Secondary safety parameter - anthropometric measures", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks after enrolment"
            }, 
            {
                "description": "serum albumin", 
                "measure": "Nutritional status - biochemical markers", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks after enrolment"
            }, 
            {
                "description": "serum level of C reactive protein", 
                "measure": "Inflammation", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks after enrolment"
            }, 
            {
                "description": "Serum total cholesterol", 
                "measure": "Nutritional status - biochemical marker", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks after enrolment"
            }, 
            {
                "description": "Serum potassium level", 
                "measure": "Secondary safety parameter", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks after enrolment"
            }, 
            {
                "description": "liver enzymes: Aspartate Aminotransferase, Alanine Transaminase", 
                "measure": "Secondary safety parameter", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks after enrolment"
            }, 
            {
                "description": "Occurrence of any adverse event", 
                "measure": "Safety parameter - adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks after enrolment"
            }, 
            {
                "description": "number of withdrawals", 
                "measure": "Secondary safety parameter - withdrawals", 
                "safety_issue": "Yes", 
                "time_frame": "18 weeks after enrolment"
            }
        ], 
        "source": "Anemia Working Group Romania", 
        "sponsors": {
            "collaborator": {
                "agency": "Dr Carol Davila Teaching Hospital of Nephrology Bucharest", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Anemia Working Group Romania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}